XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome
Stéphanie Rigaud(Délégation Paris 5), Sylvain Latour(Inserm), Patrick Revy(Hôpital Necker-Enfants Malades), Geneviève de Saint Basile(Centre National de la Recherche Scientifique), Nathalie Lambert(Hôpital Necker-Enfants Malades), Pauline Soulas‐Sprauel(Université de Strasbourg), Marie‐Claude Fondanèche(Délégation Paris 5), Frédéric Rieux‐Laucat(Inserm), Véronique Mateo(Délégation Paris 5), Benoit Pasquier(Délégation Paris 5), Lionel Galicier(Assistance Publique – Hôpitaux de Paris), Françoise Le Deist(Centre National de la Recherche Scientifique), Alain Fischer(Université Claude Bernard Lyon 1)
Cited by 701
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
|Science|2000|2.6k
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
|New England Journal of Medicine|2003|1.8k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k